Lumbar Spinal Stenosis Clinical Trial
— POSTOfficial title:
A Prospective, Multi-Center, Randomized Concurrently Controlled Trial to Evaluate the Safety and Effectiveness of the Altum® Pedicle Osteotomy System for Use in Lumbar Spinal Stenosis
Verified date | July 2020 |
Source | Innovative Surgical Designs |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a pivotal Randomized Clinical trial to compare the safety and effectiveness of the Pedicle Lengthening Osteotomy Procedure with implantation of the Altum® Device to open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) in patients with symptomatic, one or two level lumbar spinal stenosis (LSS) and one level grade I degenerative spondylolisthesis requiring surgical treatment.
Status | Suspended |
Enrollment | 344 |
Est. completion date | October 26, 2024 |
Est. primary completion date | October 26, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Is a male or female patient between 40 and 80 years of age. 2. Has the diagnosis of degenerative spinal stenosis of the lumbar region (defined as L2-L5), defined by one or more of the following: a) narrowingof the mid-sagittal spinal canal (central stenosis), b) narrowing between the facet superior articular process (SAP) and the posterior intervertebral disc margin (lateral recess stenosis), c) narrowing of the nerve root foraminal canal(s) (foraminal stenosis) and has, at the same level, radiographic confirmation on plain lateral flexion/extension radiographs of a degenerative grade I spondylolisthesis at the same level, defined as at least 1% but not greater than 25%, offset between the posterior margins of the adjacent vertebral bodies at the index level. 3. Neurogenic claudication or radiculopathic symptoms including leg pain, muscle weakness, and/or sensation abnormality, with or without back pain, which is worse with extended posture and relieved by flexion, as evidenced by patient history. 4. Has pain in the leg and/or buttock that is worse with standing as compared to sitting. 5. Has radiographic confirmation on CT or MRI of moderate or greater lumbar spinal stenosis at the index level defined as > 25% reduction in area of the central and/or lateral recess and/or foraminal regions of the spinal canal as compared to the adjacent level. 6. Has radiographic confirmation on CT or MRI of compression of the thecal sac and/or cauda equina and/or nerve root(s) due to hypertrophy of the facet joints and/or ligamentum flavum thickening/buckling 7. Has undergone a 6 month or longer course of conservative therapy without sufficient relief of symptoms that has included one or more of the following interventions: physical therapy, bracing, systemic and/or injected medications. 8. Has moderate or greater impairment on the Zurich Claudication Questionnaire (ZCQ) Physical Function scale (PF) defined as a score of 2 or greater. 9. Has moderate or greater impairment on the Oswestry Disability Index defined as a score of 30 or greater. 10. Is a surgical candidate for lumbar decompressive surgery at one or two levels in the L2 through L5 region of the spine. 11. Is psychosocially, mentally and physically able to comply with all study procedures required by the study protocol including attending all scheduled visits and interventions. 12. Is able to provide voluntary, informed consent to participate in the clinical trial and has signed the informed consent documents. Exclusion Criteria: 1. Has had prior spinal surgery at any level between L1 and S1. 2. Requires more than 2 lumbar levels of surgical decompression. 3. Has a degenerative spondylolisthesis of greater than grade I defined as greater than 25% offset between the posterior margins of adjacent vertebral bodies on plain lateral flexion/extension radiographs or does not have a grade I degenerative spondylolisthesis, defined as 0% offset between the posterior margins of adjacent vertebral bodies on a plain lateral flexion/extension radiograph. 4. Has more than one level of degenerative spondylolisthesis or has spondylolisthesis located at lumbar levels which are not treated with surgical decompression. Has the diagnosis of peripheral neuropathy. 5. Has a complete motor or sensory deficit. 6. Has a pars defect. 7. Has facet joints at the implant level that are absent or fractured. 8. Has lumbar scoliosis with a Cobb angle of greater than 25o. 9. Has a disc herniation at any lumbar level requiring surgical intervention. 10. Has symptomatic hip arthritis or hip pain. 11. Has a Body Mass Index (BMI) of greater than 40. 12. Has a known allergy to titanium or titanium alloys. 13. Has osteoporosis. The SCORE (Simple Calculated Osteoporosis Risk Estimation) will be used to screen subjects who require DEXA; Subjects with T-score < -2.5 (per The World Health Organization definition) will be excluded. 14. Has a history of Paget's disease, osteomalacia, or any other metabolic bone disease. 15. Has a history of rheumatoid arthritis or other systemic autoimmune disease. 16. Requires medications or drugs known to interfere with bone/soft tissue healing (e.g., chronic systemic corticosteroids). Corticosteroids used for 6 weeks or less are not an exclusion criteria. 17. Has insulin dependent diabetes mellitus. 18. Has cauda equina syndrome, defined as neural compression in the lumbar spine causing neurogenic bowel (rectal incontinence) or neurogenic bladder (bladder retention or incontinence) dysfunction. 19. Only has axial back pain with no leg or buttock pain. 20. Has back or leg pain of unknown etiology. 21. Has evidence or the diagnosis of significant peripheral vascular disease (e.g. diminished or absent dorsalis pedis or posterior tibial pulses) 22. The patient currently has any of the following: schizophrenia, bipolar disorder, major depression, major psychotic disorder, and substance or alcohol abuse or dependency as defined by the DSM V. 23. Has participated in a clinical trial of another investigational drug or device within the past 2 years. 24. Has an active, chronic infection, either systemic or local. |
Country | Name | City | State |
---|---|---|---|
United States | Rothman Institute | Bryn Mawr | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Innovative Surgical Designs |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Zurich Claudication Questionnaire (ZCQ) | Clinically significant improvement in outcomes ZCQ scores compared to baseline Improvement in physical function by > 0.5 points Improvement in symptom severity by > 0.5 points "Satisfied" or "somewhat satisfied" as defined by a score of < 2.5 points on the patient satisfaction domain |
24 months | |
Primary | No reoperations | No re-operations, removals, revisions or supplemental fixation at the index level. | Index level | |
Primary | Adjacent level surgery | No additional surgery at the adjacent levels | 24 months | |
Primary | Adverse events | No major device-related adverse events | 24 months | |
Primary | Radiological Success | Presence of continuous bridging bone across both pedicle osteotomy sites on CT scanning, No evidence of bridging bone between the upper and lower vertebral endplates on CT scanning, and evidence of continued motion as demonstrated on flexion-extension films Absence of a major device related adverse event (device breakage, disassembly or migration) |
24 months | |
Secondary | Oswestry Disability Index | Improvement in Oswestry Disability Index v2.1a > 15 points from baseline to 24 months | 24 months | |
Secondary | EQ5D | Change in EQ5D from baseline to 24 months | 24 months | |
Secondary | SF-12 | Change in SF-12v2.0™ from baseline to 24 months | 24 months | |
Secondary | Pain Visual Analog Scale (VAS) for Back and Leg | Pain Visual Analog Scale (VAS) is a measure of pain intensity. It is a continuous scale comprised of a 100mm line ranging from 0 (no pain) to 10 (worst imaginable pain). Patients mark a line on the scale depicting their pain level. A VAS score is determined by measuring where the mark is made relative to the ends of the line. VAS will be done separately for low back, right leg and left leg pain.Improvement in VAS for back, right leg and left leg pain of 20/100mm from baseline to 24 months | 24 months | |
Secondary | Cost | Direct costs of the episode of care | Index surgery | |
Secondary | Opioid use | Use of opioid analgesics | baseline to 24 months | |
Secondary | Return to work | Patient will report the date of which they return to work | Anytime from discharge after surgery up to 24 months (+/- 60 days) | |
Secondary | Daily activities | Time for return to usual daily activities | baseline to 24 months | |
Secondary | Patient Satisfaction | A series of questions intended to assess the effects of the procedure itself on your well-being, and does not refer to the hospital or its staff. One out of 5 statements will be chosen based on the patient's level of satisfaction: The procedure results met my expectations and I feel better than I did before surgery; The procedure improved my condition enough that I would go through it again for the same outcome; The procedure helped me but I would not go through it again for the same outcome; I feel the same or worse compared to before surgery. Furthermore, patients will be ask to choose one statement based on how they feel today compared to their last visit: I feel much better; I feel somewhat better; I feel somewhat worse; I feel much worse. |
24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04795284 -
Biomechanical Parameters of Gait in Patients With Symptomatic Lumbar Spinal Stenosis and Healthy Elderly.
|
||
Recruiting |
NCT04066296 -
Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine
|
Phase 2 | |
Active, not recruiting |
NCT05114135 -
TLIF Osteo3 ZP Putty Study (Also Known as the TOP Fusion Study)
|
N/A | |
Recruiting |
NCT06057428 -
Activity Levels Amongst Patients With Lumbar Spinal Stenosis
|
||
Recruiting |
NCT06075862 -
Balance Amongst Patients With Lumbar Spinal Stenosis
|
||
Recruiting |
NCT05527145 -
Spinal Stenosis and Listhesis Treated With Percutaneous Interspinous Spacer: a Non-surgical Trial
|
N/A | |
Recruiting |
NCT01902979 -
The Spinal Stenosis Pedometer and Nutrition e-Health Lifestyle Intervention (SSPANLI) Trial
|
N/A | |
Completed |
NCT00749073 -
The Vertos MILD™ Preliminary Patient Evaluation Study
|
N/A | |
Completed |
NCT00527527 -
Chiropractic Dosage for Lumbar Stenosis
|
Phase 2 | |
Completed |
NCT00405691 -
Safety and Effectiveness Study of the TOPS System, a Total Posterior Arthroplasty Implant Designed to Alleviate Pain Resulting From Moderate to Severe Lumbar Stenosis
|
Phase 3 | |
Completed |
NCT03194607 -
Quantitative Evaluation of Motor Function Before and After Surgery for Degenerative Lumbar Spinal Stenosis
|
||
Recruiting |
NCT06034405 -
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
|
||
Completed |
NCT06079580 -
Patients With Lumbar Spinal Stenosis With Balance Disorder
|
||
Recruiting |
NCT05523388 -
Role of Spinal Load in the Pathophysiology of Lumbar Spinal Stenosis
|
||
Completed |
NCT04587401 -
The Effects of Anesthesia on Cerebral Perfusion in Patients With High Blood Pressure
|
N/A | |
Completed |
NCT04563793 -
Postmarket Outcomes Study for Evaluation of the Superion™ Spacer
|
||
Completed |
NCT02258672 -
Preoperative Rehabilitation for Patients Undergoing Surgery for Lumbar Spinal Stenosis
|
N/A | |
Completed |
NCT02260401 -
Long Term Outcomes of Lumbar Epidural Steroid Injections for Spinal Stenosis
|
N/A | |
Completed |
NCT01994512 -
Swedish Spinal Stenosis Study
|
N/A | |
Completed |
NCT00401518 -
A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis
|
N/A |